[Development of cancer chemotherapy. Cytoprotective agents].
Lopez
M
M
Istituto Regina Elena per lo Studio e la Cura dei Tumori, Roma, Italia.
D000478:Alkylation; D004999:Amifostine / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D002614:Chelating Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D019610:Cytoprotection; D005029:Ethylenediamines / Q000627:therapeutic use; D005260:Female; D005978:Glutathione / Q000627:therapeutic use; D005998:Glycine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006868:Hydrolysis; D008297:Male; D015080:Mesna / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D020011:Protective Agents / Q000627:therapeutic use*; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D051381:Rats; D011929:Razoxane / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D002614:Chelating Agents; D005029:Ethylenediamines; D020011:Protective Agents; D011837:Radiation-Protective Agents; D011929:Razoxane; C059866:ICRF 198; D005978:Glutathione; D004999:Amifostine; D015080:Mesna; D005998:Glycine